POLARAMINE Drug Patent Profile
✉ Email this page to a colleague
When do Polaramine patents expire, and when can generic versions of Polaramine launch?
Polaramine is a drug marketed by Schering and is included in two NDAs.
The generic ingredient in POLARAMINE is dexchlorpheniramine maleate. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dexchlorpheniramine maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Polaramine
A generic version of POLARAMINE was approved as dexchlorpheniramine maleate by PAI HOLDINGS PHARM on March 23rd, 1984.
Summary for POLARAMINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 60 |
Clinical Trials: | 1 |
Patent Applications: | 1,569 |
Formulation / Manufacturing: | see details |
DailyMed Link: | POLARAMINE at DailyMed |
Recent Clinical Trials for POLARAMINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University Hospital, Bordeaux | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for POLARAMINE
US Patents and Regulatory Information for POLARAMINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | POLARAMINE | dexchlorpheniramine maleate | SYRUP;ORAL | 086837-001 | Jul 19, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Schering | POLARAMINE | dexchlorpheniramine maleate | TABLET;ORAL | 086835-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |